modelJ01DH06
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | TebipenemPivoxil | |
| ATC code: | J01DH06 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 15.5 | L |
| clearance: | 13.1 | L/hr |
| other parameters in model implementation | ||
Tebipenem pivoxil is an orally bioavailable prodrug of tebipenem, which is a carbapenem antibiotic used primarily for the treatment of multidrug-resistant bacterial infections, especially respiratory tract and urinary tract infections. Tebipenem pivoxil has been approved in Japan for pediatric use in infections caused by susceptible strains, but as of 2024 it is not widely approved outside Japan for routine use.
Pharmacokinetics
Population pharmacokinetic parameters in healthy adult volunteers after a single oral dose of 200 mg tebipenem pivoxil.
References
Ganesan, H, et al., & Rubino, CM (2023). Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide. Antimicrobial agents and chemotherapy 67(6) e0145122–None. DOI:10.1128/aac.01451-22 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37191505
Sato, N, et al., & Totsuka, K (2008). Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug metabolism and pharmacokinetics 23(6) 434–446. DOI:10.2133/dmpk.23.434 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19122338
Abouelhassan, Y, et al., & Asempa, TE (2022). Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. The Journal of antimicrobial chemotherapy 78(1) 296–301. DOI:10.1093/jac/dkac399 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36424364
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)